Evidence Connections

Follow the evidence beyond the paper.

Follow source-linked research projects, organizations, FDA application actions, compound targets and genetic studies.

Explore relationships stated by the original sources. Each number opens its exact collection—not a count of extra papers or proven treatments.

FDA Drugs@FDA application records

7,807

Indexed connections · inspect this exact collection

FDA application actionApril 18, 2023

clofarabine

Approved submission · SUPPL 2

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 17, 2023

Prednisone

Approved submission · SUPPL 18

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 13, 2023

Everolimus

Approved submission · SUPPL 31

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 4, 2023

Sirolimus

Approved submission · SUPPL 1

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 3, 2023

Pembrolizumab

Approved submission · SUPPL 136

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 3, 2023

Pembrolizumab

Approved submission · SUPPL 136

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionMarch 30, 2023

Methotrexate

Approved submission · SUPPL 2

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionMarch 28, 2023

Pembrolizumab

Approved submission · SUPPL 132

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionMarch 28, 2023

Pembrolizumab

Approved submission · SUPPL 132

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionMarch 21, 2023

Sirolimus

Approved submission · SUPPL 1

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionMarch 17, 2023

hydrochlorothiazide

Approved submission · SUPPL 28

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionMarch 17, 2023

hydrochlorothiazide

Approved submission · SUPPL 33

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionMarch 17, 2023

hydrochlorothiazide

Approved submission · SUPPL 35

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionMarch 17, 2023

hydrochlorothiazide

Approved submission · SUPPL 43

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionMarch 17, 2023

hydrochlorothiazide

Approved submission · SUPPL 71

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionMarch 16, 2023

hydrochlorothiazide

Approved submission · SUPPL 43

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionMarch 9, 2023

Acyclovir

Approved submission · ORIG 1

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionMarch 3, 2023

Sildenafil citrate

Approved submission · SUPPL 16

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionMarch 3, 2023

Sildenafil citrate

Approved submission · SUPPL 16

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionMarch 1, 2023

hydrochlorothiazide

Approved submission · SUPPL 5

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionFebruary 28, 2023

Acyclovir

Approved submission · ORIG 1

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionFebruary 28, 2023

ganirelix acetate

Approved submission · ORIG 1

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionFebruary 24, 2023

hydrochlorothiazide

Approved submission · ORIG 1

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionFebruary 24, 2023

Everolimus

Approved submission · SUPPL 4

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →